全身糖皮质激素治疗慢性阻塞性肺疾病急性加重期患者的效果分析

Analysis of the effect of systemic glucocorticoids on patients with acute exacerbation of chronic obstructive pulmonary disease

目的分析慢性阻塞性肺疾病(慢阻肺,COPD)急性加重期患者使用全身糖皮质激素治疗的效果。方法 66例慢性阻塞性肺疾病急性加重期患者作为研究对象,采用抽签法分为实验组与对照组,每组33例。对照组患者采用常规治疗,实验组患者在对照组基础上联合全身糖皮质激素治疗。比较两组患者治疗效果及肺功能指标[第1秒用力呼气容积(FEV1)、最大呼气中段流量(MMEF)、用力肺活量(FVC)]。结果实验组患者的治疗总有效率96.97%显著高于对照组的72.73%,差异具有统计学意义(P<0.05)。治疗前,两组患者FEV1、MMEF、FVC水平比较差异无统计学意义(P>0.05);治疗后,实验组患者的FEV1、MMEF、FVC分别为(1.82±0.25)L、(1.86±0.35)L/s、(3.13±0.25)L,均显著高于对照组的(1.27±0.36)L、(1.20±0.23)L/s、(2.16±0.35)L,差异具有统计学意义(P<0.05)。结论慢性阻塞性肺疾病急性加重期患者采用全身糖皮质激素进行加减治疗,能改善患者的肺功能,具有较高的临床应用价值。

Objective To analyze the effect of systemic glucocorticoids on patients with acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods A total of 66 patients with acute exacerbation of chronic obstructive pulmonary disease as the research subjects were divided into experimental group and control group by lottery method,with 33 cases in each group.Patients in the control group was treated with conventional treatment,and patients in the experimental group were treated with systemic glucocorticoids on the basis of the control group.The therapeutic effects and pulmonary function indexes[forced expiratory volume in the 1 st second(FEV1),maximum mid-expiratory flow(MMEF),and forced vital capacity(FVC)] were compared between the two groups.Results The total effective rate 96.97% in the experimental group was significantly higher than 72.73% in the control group,and the difference was statistically significant(P<0.05).Before treatment,the FEV1,MMEF,and FVC of the two groups were not significantly different(P>0.05).After treatment,the FEV1,MMEF,and FVC of the experimental group were(1.82±0.25) L,(1.86±0.35) L/s,and(3.13±0.25) L,which were significantly higher than(1.27±0.36) L,(1.20±0.23) L/s,and(2.16±0.35) L of the control group,and the difference was statistically significant(P<0.05).Conclusion Systemic glucocorticosteroids can improve the pulmonary function of patients with acute exacerbation of chronic obstructive pulmonary disease,and has high clinical application value.